U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT06887738) titled 'Study of NM8074 in Patients with Dermatomyositis (DM)' on March 07.
Brief Summary: This is a Phase II, open-label, multicenter study to evaluate the safety and efficacy of NM8074 administered via intravenous infusion in patients with Dermatomyositis (DM).
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Dermatomyositis
Intervention:
DRUG: NM8074
NM8074 will be administered as an intravenous infusion at a dose of 20mg/kg
Recruitment Status: NOT_YET_RECRUITING
Sponsor: NovelMed Therapeutics
Published by HT Digital Content Services with permission from Health Daily Digest....